Research demonstrated that combining interleukin-2 (IL-2)-armed OVs with TIL therapy promoted tumor-specific TIL accumulation in hypoimmunogenic tumors, while reducing the proportion of exhausted PD-1hi Tim-3+ CD8+ cells and Tregs. This evidence concerns the gene HAVCR2 and neoplasm.